[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
Identifieur interne : 002F07 ( PubMed/Checkpoint ); précédent : 002F06; suivant : 002F08[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
Auteurs : Brad A. Racette [États-Unis] ; Jo Ann Antenor ; Lori Mcgee-Minnich ; Stephen M. Moerlein ; Tom O. Videen ; Vikas Kotagal ; Joel S. PerlmutterSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Adult, Antiparkinson Agents (therapeutic use), Brain (metabolism), Carbidopa (therapeutic use), Drug Combinations, Female, Fluorodeoxyglucose F18 (diagnostic use), Gait, Humans, Levodopa (therapeutic use), Magnetic Resonance Imaging, Manganese Poisoning (blood), Manganese Poisoning (complications), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (etiology), Parkinson Disease (pathology), Positron-Emission Tomography, Radiopharmaceuticals (diagnostic use).
- MESH :
- chemical , diagnostic use : Fluorodeoxyglucose F18, Radiopharmaceuticals.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- blood : Manganese Poisoning.
- complications : Manganese Poisoning.
- drug therapy : Parkinson Disease.
- etiology : Parkinson Disease.
- metabolism : Brain.
- pathology : Parkinson Disease.
- Adult, Drug Combinations, Female, Gait, Humans, Magnetic Resonance Imaging, Middle Aged, Positron-Emission Tomography.
Abstract
Manganese exposure reportedly causes a clinically and pathophysiologically distinct syndrome from idiopathic Parkinson's disease (PD). We describe the clinical features and results of positron emission tomography with 6-[18F]fluorodopa ([18F]FDOPA PET) of a patient with parkinsonism occurring in the setting of elevated blood manganese. The patient developed parkinsonism associated with elevated serum manganese from hepatic dysfunction. [18F]FDOPA PET demonstrated relatively symmetric and severely reduced [18F]FDOPA levels in the posterior putamen compared to controls. The globus pallidum interna had increased signal on T1-weighted magnetic resonance imaging (MRI) images. We conclude that elevated manganese exposure may be associated with reduced striatal [18F]FDOPA uptake, and MRI may reveal selective abnormality within the internal segment of the pallidum. This case suggests that the clinical and pathophysiological features of manganese-associated parkinsonism may overlap with that of PD.
DOI: 10.1002/mds.20381
PubMed: 15648057
Affiliations:
- États-Unis
- Missouri (État)
- Saint-Louis (Missouri)
- École de médecine (Université Washington de Saint-Louis)
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15648057Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[18F]FDOPA PET and clinical features in parkinsonism due to manganism.</title><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName><placeName><settlement type="city">Saint-Louis (Missouri)</settlement><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Antenor, Jo Ann" sort="Antenor, Jo Ann" uniqKey="Antenor J" first="Jo Ann" last="Antenor">Jo Ann Antenor</name></author><author><name sortKey="Mcgee Minnich, Lori" sort="Mcgee Minnich, Lori" uniqKey="Mcgee Minnich L" first="Lori" last="Mcgee-Minnich">Lori Mcgee-Minnich</name></author><author><name sortKey="Moerlein, Stephen M" sort="Moerlein, Stephen M" uniqKey="Moerlein S" first="Stephen M" last="Moerlein">Stephen M. Moerlein</name></author><author><name sortKey="Videen, Tom O" sort="Videen, Tom O" uniqKey="Videen T" first="Tom O" last="Videen">Tom O. Videen</name></author><author><name sortKey="Kotagal, Vikas" sort="Kotagal, Vikas" uniqKey="Kotagal V" first="Vikas" last="Kotagal">Vikas Kotagal</name></author><author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20381</idno><idno type="RBID">pubmed:15648057</idno><idno type="pmid">15648057</idno><idno type="wicri:Area/PubMed/Corpus">003162</idno><idno type="wicri:Area/PubMed/Curation">003162</idno><idno type="wicri:Area/PubMed/Checkpoint">002F07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[18F]FDOPA PET and clinical features in parkinsonism due to manganism.</title><author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName><placeName><settlement type="city">Saint-Louis (Missouri)</settlement><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Antenor, Jo Ann" sort="Antenor, Jo Ann" uniqKey="Antenor J" first="Jo Ann" last="Antenor">Jo Ann Antenor</name></author><author><name sortKey="Mcgee Minnich, Lori" sort="Mcgee Minnich, Lori" uniqKey="Mcgee Minnich L" first="Lori" last="Mcgee-Minnich">Lori Mcgee-Minnich</name></author><author><name sortKey="Moerlein, Stephen M" sort="Moerlein, Stephen M" uniqKey="Moerlein S" first="Stephen M" last="Moerlein">Stephen M. Moerlein</name></author><author><name sortKey="Videen, Tom O" sort="Videen, Tom O" uniqKey="Videen T" first="Tom O" last="Videen">Tom O. Videen</name></author><author><name sortKey="Kotagal, Vikas" sort="Kotagal, Vikas" uniqKey="Kotagal V" first="Vikas" last="Kotagal">Vikas Kotagal</name></author><author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiparkinson Agents (therapeutic use)</term><term>Brain (metabolism)</term><term>Carbidopa (therapeutic use)</term><term>Drug Combinations</term><term>Female</term><term>Fluorodeoxyglucose F18 (diagnostic use)</term><term>Gait</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Imaging</term><term>Manganese Poisoning (blood)</term><term>Manganese Poisoning (complications)</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (etiology)</term><term>Parkinson Disease (pathology)</term><term>Positron-Emission Tomography</term><term>Radiopharmaceuticals (diagnostic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Fluorodeoxyglucose F18</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Manganese Poisoning</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Manganese Poisoning</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Combinations</term><term>Female</term><term>Gait</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Middle Aged</term><term>Positron-Emission Tomography</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Manganese exposure reportedly causes a clinically and pathophysiologically distinct syndrome from idiopathic Parkinson's disease (PD). We describe the clinical features and results of positron emission tomography with 6-[18F]fluorodopa ([18F]FDOPA PET) of a patient with parkinsonism occurring in the setting of elevated blood manganese. The patient developed parkinsonism associated with elevated serum manganese from hepatic dysfunction. [18F]FDOPA PET demonstrated relatively symmetric and severely reduced [18F]FDOPA levels in the posterior putamen compared to controls. The globus pallidum interna had increased signal on T1-weighted magnetic resonance imaging (MRI) images. We conclude that elevated manganese exposure may be associated with reduced striatal [18F]FDOPA uptake, and MRI may reveal selective abnormality within the internal segment of the pallidum. This case suggests that the clinical and pathophysiological features of manganese-associated parkinsonism may overlap with that of PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15648057</PMID><DateCreated><Year>2005</Year><Month>04</Month><Day>13</Day></DateCreated><DateCompleted><Year>2005</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>[18F]FDOPA PET and clinical features in parkinsonism due to manganism.</ArticleTitle><Pagination><MedlinePgn>492-6</MedlinePgn></Pagination><Abstract><AbstractText>Manganese exposure reportedly causes a clinically and pathophysiologically distinct syndrome from idiopathic Parkinson's disease (PD). We describe the clinical features and results of positron emission tomography with 6-[18F]fluorodopa ([18F]FDOPA PET) of a patient with parkinsonism occurring in the setting of elevated blood manganese. The patient developed parkinsonism associated with elevated serum manganese from hepatic dysfunction. [18F]FDOPA PET demonstrated relatively symmetric and severely reduced [18F]FDOPA levels in the posterior putamen compared to controls. The globus pallidum interna had increased signal on T1-weighted magnetic resonance imaging (MRI) images. We conclude that elevated manganese exposure may be associated with reduced striatal [18F]FDOPA uptake, and MRI may reveal selective abnormality within the internal segment of the pallidum. This case suggests that the clinical and pathophysiological features of manganese-associated parkinsonism may overlap with that of PD.</AbstractText><CopyrightInformation>Copyright 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Racette</LastName><ForeName>Brad A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antenor</LastName><ForeName>Jo Ann</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>McGee-Minnich</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Moerlein</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Videen</LastName><ForeName>Tom O</ForeName><Initials>TO</Initials></Author><Author ValidYN="Y"><LastName>Kotagal</LastName><ForeName>Vikas</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23NS43351</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS41509</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C009265">carbidopa, levodopa drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002230">Carbidopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019788">Fluorodeoxyglucose F18</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005684">Gait</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020149">Manganese Poisoning</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D049268">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20381</ArticleId><ArticleId IdType="pubmed">15648057</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Missouri (État)</li></region><settlement><li>Saint-Louis (Missouri)</li></settlement><orgName><li>École de médecine (Université Washington de Saint-Louis)</li></orgName></list><tree><noCountry><name sortKey="Antenor, Jo Ann" sort="Antenor, Jo Ann" uniqKey="Antenor J" first="Jo Ann" last="Antenor">Jo Ann Antenor</name><name sortKey="Kotagal, Vikas" sort="Kotagal, Vikas" uniqKey="Kotagal V" first="Vikas" last="Kotagal">Vikas Kotagal</name><name sortKey="Mcgee Minnich, Lori" sort="Mcgee Minnich, Lori" uniqKey="Mcgee Minnich L" first="Lori" last="Mcgee-Minnich">Lori Mcgee-Minnich</name><name sortKey="Moerlein, Stephen M" sort="Moerlein, Stephen M" uniqKey="Moerlein S" first="Stephen M" last="Moerlein">Stephen M. Moerlein</name><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name><name sortKey="Videen, Tom O" sort="Videen, Tom O" uniqKey="Videen T" first="Tom O" last="Videen">Tom O. Videen</name></noCountry><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002F07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15648057
|texte= [18F]FDOPA PET and clinical features in parkinsonism due to manganism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15648057" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |